Document is current
Any future updates will be listed below
-
Authors
Reddy, Yogesh N. V.
Carter, Rickey E. http://orcid.org/0000-0002-0818-273X
Sundaram, Varun
Kaye, David M. http://orcid.org/0000-0003-4058-0372
Handoko, M. Louis http://orcid.org/0000-0002-8942-7865
Tedford, Ryan J. http://orcid.org/0000-0001-9045-7722
Andersen, Mads J. http://orcid.org/0000-0002-9320-8227
Sharma, Kavita
Obokata, Masaru
Verbrugge, Frederik H. http://orcid.org/0000-0003-0599-9290
Borlaug, Barry A. http://orcid.org/0000-0001-9375-0596
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL128526, R01 HL162828, U01 HL160226, K23HL164901)
- License Information
-
More Information
Article History
Received: 21 November 2023
Accepted: 18 June 2024
First Online: 12 July 2024
Competing interests
: B.A.B. receives research support from the NIH and the US Department of Defense, as well as research grant funding from AstraZeneca, Axon, GSK, Medtronic, Mesoblast, Novo Nordisk and Tenax Therapeutics. He has served as a consultant for Actelion, Amgen, Aria, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Janssen, Merck and Novo Nordisk. B.A.B. and S.J.A. are named inventors (US patent no. 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Y.N.V.R. receives research support from the NIH, Sleep Number, Bayer, Merck and United Pharmaceuticals. M.L.H. reported receiving grants from the Dutch Heart Foundation and educational, speaker and consultancy fees from Novartis, Boehringer Ingelheim, AstraZeneca, Vifor Pharma, Bayer, Merck, Abbott, Daiichi Sankyo and Quin outside the submitted work. R.J.T. reports no direct conflicts of interest related to this manuscript. He is co-chair of the Pulmonary Hypertension due to Left Heart Disease Task Force for the 7th World Symposium on Pulmonary Hypertension. He reports general disclosures that include consulting relationships with Abbott, Acorai, Aria CV, Acceleron/Merck, Alleviant, CareDx, Cytokinetics, Edwards LifeSciences, Gradient, Lexicon Pharmaceuticals, Medtronic and United Therapeutics. R.J.T. serves on the steering committees for Merck, Edwards and Abbott, as well as a research advisory board member for Abiomed. He also does hemodynamic core laboratory work for Merck. M.J.A. reports no direct conflicts of interest related to this manuscript. He reports a consulting relationship with Johnson & Johnson. F.H.V. reports no direct conflicts of interest related to this manuscript. He reports a consulting relationship with Abbott Laboratories, Abiomed, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb Belgium, Daiichi Sankyo, Menarini Benelux, MSD, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics and Qompium. The other authors declare no competing interests.
